cetuximab + encorafenib BRAF V600E Colorectal Carcinoma Metastatic Subsequent line cetuximab, +1 more drug targeted therapy
binimetinib + encorafenib BRAF V600E, +1 more biomarker Melanoma Metastatic, +1 more state binimetinib, +1 more drug targeted therapy
dabrafenib + trametinib BRAF V600E Thyroid Gland Undifferentiated (Anaplastic) Carcinoma Locally advanced, +1 more state No standard/acceptable treatment dabrafenib, +1 more drug targeted therapy
dabrafenib + trametinib BRAF V600E, +1 more biomarker Melanoma Lymph node involvement Adjuvant dabrafenib, +1 more drug targeted therapy
dabrafenib + trametinib BRAF V600E Non-Small Cell Lung Carcinoma Metastatic dabrafenib, +1 more drug targeted therapy
dabrafenib + trametinib BRAF V600E, +1 more biomarker Melanoma Metastatic, +1 more state dabrafenib, +1 more drug targeted therapy
cobimetinib + vemurafenib BRAF V600E, +1 more biomarker Melanoma Metastatic, +1 more state cobimetinib, +1 more drug targeted therapy
trametinib BRAF V600E, +1 more biomarker Melanoma Metastatic, +1 more state trametinib targeted therapy
cetuximab + encorafenib BRAF V600E Colorectal Carcinoma Advanced, +1 more state Subsequent line cetuximab, +1 more drug targeted therapy
cobimetinib + vemurafenib BRAF V600E Ganglioglioma, +2 more conditions Adjuvant cobimetinib, +1 more drug targeted therapy
Cancer Search
